论文部分内容阅读
目的临床观察恩替卡韦联合蒙药优宁-8味丸治疗慢性乙型肝炎(chronic hepatitis B,CHB)的血清酶影响。方法 38例慢性乙型肝炎患者,观察给予恩替卡韦分散片0.5mg,1次/d,口服;同时服用蒙药优宁-8味丸3.0g,2次/d,疗程均为8wk。结果治疗8wk后,观察丙氨酸转氨酶(alanine aminotransferase,ALT)、谷草转氨酶(glutamic-oxalacetic transaminase,AST)、和谷氨酰转移酶(γ-GT)值分别为33.54±17.26U/L,36.48±20.83U/L和26.26±14.10U/L均显著低于治疗前(70.10±90.76U/L、72.93±103.13U/L和89.26±21.30U/L,P<0.05),差异均具有显著性意义。治疗过程中,患者均未见明显不良反应。结论恩替卡韦联合蒙药优宁-8味散可以有效地改善肝功能,同时不影响恩替卡韦抑制乙型肝炎病毒复制的作用,值得临床推广应用。
Objective To observe the effect of entecavir combined with Mongolian yunning -8 taste pill in treating chronic hepatitis B (CHB). Methods Thirty-eight patients with chronic hepatitis B were treated with entecavir dispersible tablets 0.5 mg once daily for oral administration. Meanwhile, Mongolian yunning-8 flavored pill (3.0 g twice daily) was given for 8 weeks. Results Alanine aminotransferase (ALT), glutamic-oxalacetic transaminase (AST) and glutamyl transferase (γ-GT) were observed after 8 weeks of treatment. The values were 33.54 ± 17.26U / L, 36.48 ± 20.83U / L and 26.26 ± 14.10U / L were significantly lower than before treatment (70.10 ± 90.76U / L, 72.93 ± 103.13U / L and 89.26 ± 21.30U / L, P <0.05), the differences were significant significance. During the treatment, patients showed no obvious adverse reactions. Conclusion Entecavir combined with Mongolian medicine Youning-8 powder can effectively improve liver function without affecting the effect of entecavir on hepatitis B virus replication, which is worthy of clinical application.